Profile
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*
*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1
- Trurapi SmPC (April 2023)
- NHS DM+M: REF-161114. Available at: https://services.nhsbsa.nhs.uk/dmd-browser Date accessed: April 2023
- Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
- Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.
Abbreviations:
EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.
References:
Diabetes Stories
Watch peer-to-peer videos of payors and healthcare professionals sharing best practices of adopting a rapid acting insulin biosimilar.
Some of these videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.
Nichola Hughes – Hospital Diabetes Specialist Nurse
Paula Johnston - Lead Inpatient Diabetes Specialist Nurse
Length: 02:22
In this video you can learn from Paula Johnston how she achieved a positive patient experience with this biosimilar and how she carried out an opportunistic switch of existing patients, when appropriate.
Dr Saqib Mahmud - Primary Care Consultant
Length: 02:55
In this video you can learn from Dr. Saqib Mahmud why he decided to prescribe a rapid acting insulin biosimilar and get practical recommendations when switching patients to a rapid acting insulin biosimilar.
Dr Duncan Browne - Consultant Endocrinologist
Length: 03:32
In this video you can learn why Duncan Browne decided to prescribe a rapid acting insulin biosimilar, how he aligned internally the local service to drive the adoption of this biosimilar in his local region and find out how the patient experience has been with this biosimilar.
Amanda Veall - Diabetes Specialist Nurse
Length: 04:16
In this video you can learn why Amanda Veall decided to prescribe a rapid acting insulin biosimilar, how she collaborated with clinical teams to drive the adoption of this biosimilar in her local region and find out how the patient experience has been with this biosimilar.
Marcus Jones - Formulary Pharmacist
Length: 03:43
In this video you can learn how Marcus Jones accelerated the adoption of a rapid acting biosimilar insulin in his local region and how he collaborated with clinical teams to make a positive start and switch.
Start and Switch
Watch and download resources to support your rapid acting insulin adoption.
Trurapi Leaflet
This leaflet gives you an overview of the clinical evidence, price comparison of Trurapi® versus NovoRapid® and information on 1:1 dosing and the different presentations available.
Formulary FAQ
This FAQ document provides factual and technical information about Trurapi® to support you with relevant documentation for local formulary applications.
Trurapi Poster
Pharmacists and other Healthcare Professionals can print this poster and put it in drug fridges to provide information about Trurapi.
.png)
Slide Deck
This slide deck can be used to support Health Care Professional training on Trurapi®. It gives an overview of the clinical evidence, information on 1:1 dosing, the different presentations available and price comparison of Trurapi® versus NovoRapid®.
Retailer Query
This document supports medicines management teams and clinical customers to deal with retailer queries on how to purchase Trurapi®️.
Diabetes Stories
Length: 04:02
You can watch briefly how a payor, an endocrinologist and a diabetes specialist nurse implemented a rapid acting biosimilar insulin in their local region and how they collaborated with clinical teams and patients to make a positive start and switch.
How have your colleagues implemented Biosimilar insulins?
Get insights through personalised peer-to-peer interactions from across the country.
MAT-XU-2201545 (v3.0)
Date of Preparation: February 2023
MAT-XU-2205461 (v6.0)
Date of Preparation: April 2023
